Xorte logo

News Markets Groups

USA | Europe | Asia | World| Stocks | Commodities



Add a new RSS channel

 
 


Keywords

2023-05-26 02:15:41| Engadget

Turns out Elon Musk's FDA prediction was only off by about a month. After reportedly denying the company's overtures in March, the FDA approved Neuralink's application to begin human trials of its prototype Link brain-computer interface (BCI) on Thursday. Founded in 2016, Neuralink aims to commercialize BCIs in wide-ranging medical and therapeutic applications from stroke and spinal cord injury (SCI) rehabilitation, to neural prosthetic controls, to the capacity "to rewind memories or download them into robots," Neuralink CEO Elon Musk promised in 2020. BCIs essentially translate the analog electrical impulses of your brain (monitoring it using hair-thin electrodes delicately threaded into that grey matter) into the digital 1's and 0's that computers understand. Since that BCI needs to be surgically installed in a patient's noggin, the FDA which regulates such technologies requires that companies conduct rigorous safety testing before giving its approval for commercial use. In March, the FDA rejected Neuralink's application to begin human trials reportedly in part due to all the test animals that kept dying after having the prototype BCI implanted. According to internal documents acquired by Reuters in December, more than 1,500 animals had been killed in the development of the Neuralink BCI since 2018. The US Department of Agriculture's (USDA) Inspector General has since launched an investigation into those allegations.  The FDA's reticence was also born from concerns about the design and function of the interface when implanted in humans. "The agencys major safety concerns involved the devices lithium battery; the potential for the implants tiny wires to migrate to other areas of the brain; and questions over whether and how the device can be removed without damaging brain tissue," current and former Neuralink employees told Reuters in March.While Neuralink has obtained FDA approval to begin its study, the company is not yet seeking volunteers. This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people," Neuralink Tweeted on Thursday. "Recruitment is not yet open for our clinical trial."  This article originally appeared on Engadget at https://www.engadget.com/neuralink-receives-fda-clearance-to-begin-human-trials-of-its-brain-computer-interface-001504243.html?src=rss


Category: Marketing and Advertising

 

Latest from this category

08.05Which US Jobs Are Using Generative AI the Most? [Infographic]
08.05The Secret to B2B Event Success: The Virtual Sandwich Method
08.05AI in B2B Marketing: Connecting Adtech and Martech for Full-Funnel Growth
08.05Lidl cuts cartoon marketing from low-nutrition products
07.05Are AI Customer Experience Agents Helpful?
07.05What Does the Marketer of the Future Look Like?
07.05Using AI, BBC Maestro resurrects Agatha Christie as a writing teacher
06.05The State of B2B Influencer Marketing in 2025
Marketing and Advertising »

All news

09.05Geopolitical tensions not yet a red flag for investors: Cameron Brandt
09.05Ravi Infrabuild Projects files draft papers with Sebi to raise Rs 1,100 cr through IPO
09.05Indias Kamikaze drone strike on Pakistan boosts this Israeli stock with an Adani connection
09.05Hotel stocks sink up to 7% after Pakistan's drone attacks in India
09.05Trump hints tariffs on China may drop as talks set to begin
09.05MCX shares fall nearly 7% after reporting Q4 results
09.05Kalyan Jewellers shares jump 3% after Q4 net profit rises 36% YoY to Rs 188 crore
09.05India UK FTA paves way for similar agreements with countries like USA, EU: Bank of Baroda
More »
Privacy policy . Copyright . Contact form .